文献速递头痛与眩晕

Eptinezumab治疗发作性丛集性头痛的疗效与安全性:随机临床试验

Efficacy and Safety of Eptinezumab in Episodic Cluster Headache: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2025-01-01

这项双盲、安慰剂对照、1:1随机试验在欧美日64个中心纳入231例发作性丛集性头痛成人患者,评估Eptinezumab 400mg静脉输注的预防效果。主要终点(第1-2周每周发作数变化)未达统计学显著性,但第2-4周应答率数值上更高,安全性良好。

要点

  • 主要终点:第1-2周每周发作数变化,Eptinezumab组与安慰剂组无统计学差异
  • 第2-4周50%应答率在Eptinezumab组数值上更高,但研究为探索性分析
  • 治疗出现的不良事件发生率两组相近,Eptinezumab总体耐受良好

核心结论

  • 在发作性丛集性头痛成人中,Eptinezumab未显著减少每周发作数,但应答率数值上更高且耐受良好。

研究设计与样本

  • 双盲、安慰剂对照、1:1随机试验(ALLEVIATE),2020年12月至2023年10月在欧美日64个中心进行。
  • 纳入231例18-75岁发作性丛集性头痛成人,随机分配Eptinezumab 400mg(n=118)或安慰剂(n=113)静脉输注。
  • 分析初始4周随机期,主要终点为第1-2周每周发作数较基线变化。

主要发现

  • 治疗出现的不良事件:Eptinezumab组25.0%(28/112),安慰剂组26.5%(31/117)。

临床怎么用

  • Eptinezumab未能显著减少丛集性头痛发作频率,主要终点阴性,不推荐作为发作性丛集性头痛的常规预防用药。
  • 应答率数值上的优势提示部分患者可能获益,但需进一步研究确认亚组人群。

局限性

  • 仅报告初始4周随机期结果,长期疗效未知。
  • 主要终点未达统计学显著性,应答率分析为次要终点,需谨慎解读。
  • 样本以男性为主(78%),结果外推需注意。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cluster headache, characterized by bouts of excruciating pain attacks, detrimentally affects health and quality of life. Eptinezumab is an anticalcitonin gene-related peptide monoclonal antibody approved for migraine prevention. OBJECTIVE: To evaluate the efficacy and safety of eptinezumab in the preventive treatment of episodic cluster headache. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, randomized (1:1) clinical trial (Eptinezumab in Participants With Episodic Cluster Headache [ALLEVIATE]) was conducted between December 2020 and October 2023. Results are from the initial 4-week randomized phase. The study took place at 64 sites across Europe, the US, and Japan. Included were adults (aged 18-75 years) with a history of episodic cluster headache for 1 or more years (with bouts lasting ≥6 weeks when untreated) and previous acute and preventive medication use. INTERVENTIONS: Eptinezumab, 400 mg, or placebo (intravenous infusion). MAIN OUTCOMES AND MEASURES: The primary end point was the change from baseline in the number of weekly attacks in weeks 1 to 2. Safety was assessed using treatment-emergent adverse events. RESULTS: Of 628 total participants screened, 320 entered the second screening period, and 231 met eligibility criteria. Of the 231 participants randomized (eptinezumab, n = 118; placebo, n = 113), 215 (93%) completed the placebo-controlled period. The participant mean (SD) age was 44 (11) years, and 178 of 229 were male (78%). At baseline, the mean (SD) weekly attacks were 15.2 (8.1) in the eptinezumab group and 15.7 (8.3) in the placebo group. There was no statistically significant difference between eptinezumab and placebo in the change from baseline in the number of weekly attacks over weeks 1 to 2 (least-squares mean [SE], -4.0 [0.93] vs -4.6 [0.89]; between-group difference, 0.7; 95% CI, -1.3 to 2.6; P = .50). More eptinezumab-treated participants achieved 50% or greater response vs placebo over week 2 (50.9% [54 of 106] vs 37.3% [41 of 110]; odds ratio [OR], 1.77; 95% CI, 1.03-3.07; P =.04), week 3 (62.5% [65 of 104] vs 43.8% [49 of 112]; OR, 2.26; 95% CI, 1.30-3.97; P =.004), and week 4 (66.7% [68 of 102] vs 50.5% [54 of 107]; OR, 2.14; 95% CI, 1.21-3.83; P =.009). Eptinezumab showed numerically larger improvements than placebo for 75% or greater response, average daily pain scores, and across other patient-reported outcomes. Treatment-emergent adverse events occurred in 25.0% of patients (28 of 112) receiving eptinezumab and 26.5% of patients (31 of 117) receiving placebo. CONCLUSIONS AND RELEVANCE: Among adults with episodic cluster headache, eptinezumab did not significantly reduce the number of attacks vs placebo, although it was associated with numerically higher responder rates and improvements in average daily pain and patient-reported outcomes. Eptinezumab was generally well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04688775.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Jensen RH, Tassorelli C, Tepper SJ, et al. Efficacy and Safety of Eptinezumab in Episodic Cluster Headache: A Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 40388178. doi:10.1001/jamaneurol.2025.1317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。